Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer

Xinan Sheng

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Genitourinary Oncology, Peking University Cancer Hospital and Institute, Beijing

Gongqian Zeng

Hunan Cancer Hospital, Changsha, China

Cuijian Zhang

Peking University First Hospital, Beijing

Qingyun Zhang

Affiliated Cancer Hospital of Guangxi Medical University, Nanning, China

Jiasheng Bian

Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China

Haitao Niu

Affiliated Hospital of Qingdao University, Qingdao, China

Jun Li

Yanxia Shi

Sun Yat-sen University Cancer Center, Guangzhou, China

Kai Yao

School of Materials Science and Engineering

Bin Hu

Ziling Liu

First Hospital of Jilin University, Changchun, China

Hong Liao

Zhixian Yu

First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China

Baiye Jin

Department of Urology, The First Affiliated Hospital, Zhejiang University School of Medicine

Peng Zhao

Tiejun Yang

Affiliated Cancer Hospital of Zhengzhou University–Henan Cancer Hospital, Zhengzhou, China

Xianling Liu

Department of Oncology, Second Xiangya Hospital, Central South University, Changsha, China

Yang Qin

Xueyi Xue

First Affiliated Hospital of Fujian Medical University, Fuzhou, China

Xin Gou

First Affiliated Hospital of Chongqing Medical University, Chongqing, China

Jian Huang

Jiang Gu

Affiliated Hospital of Guizhou Medical University, Guiyang, China

Xiaolong Qi

Lu Zhang

Guoxian Ma

RemeGen, Yantai, China

Beisong Liu

RemeGen, Yantai, China

Jianmin Fang

RemeGen, Yantai, China

Shusuan Jiang

Hunan Cancer Hospital, Changsha, China

Zhisong He

Aiping Zhou

National Cancer Center, National Clinical Research Center for Cancer, and Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing

Jun Guo